Cargando…

Comparative Assessment of Retinal Blood Flow Velocity Changes Following Brimonidine and Brinzolamide Administration Using Retinal Function Imaging

PURPOSE: Impaired ocular blood flow has been associated with the etiopathogenesis of glaucoma. Topical brimonidine lowers intraocular pressure, a major glaucoma risk factor. However, brimonidine's influence on retinal blood flow remains to be fully elucidated. Our aim was to compare the effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Enz, Tim J., Bittner, Mario, Tribble, James R., Williams, Pete A., Thiel, Michael A., Schmid, Martin K., Bachmann, Lucas M., Bochmann, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Association for Research in Vision and Ophthalmology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819484/
https://www.ncbi.nlm.nih.gov/pubmed/35103799
http://dx.doi.org/10.1167/tvst.11.2.1
_version_ 1784646072756338688
author Enz, Tim J.
Bittner, Mario
Tribble, James R.
Williams, Pete A.
Thiel, Michael A.
Schmid, Martin K.
Bachmann, Lucas M.
Bochmann, Frank
author_facet Enz, Tim J.
Bittner, Mario
Tribble, James R.
Williams, Pete A.
Thiel, Michael A.
Schmid, Martin K.
Bachmann, Lucas M.
Bochmann, Frank
author_sort Enz, Tim J.
collection PubMed
description PURPOSE: Impaired ocular blood flow has been associated with the etiopathogenesis of glaucoma. Topical brimonidine lowers intraocular pressure, a major glaucoma risk factor. However, brimonidine's influence on retinal blood flow remains to be fully elucidated. Our aim was to compare the effect of topical brimonidine and brinzolamide administration on retinal blood flow velocity in second and third order vessels in healthy adults using the retinal function imager. METHODS: In 10 healthy probands between 23 and 32 years of age, one eye was randomly selected to receive 2 treatment rounds with 3 single doses of brimonidine 2 mg/mL and brinzolamide 10 mg/mL at 12-hour intervals each. The fellow eyes served as intra-individual controls. Immediately before the first drop and 2 hours after the last drop of each treatment round, all subjects were examined, including Goldmann tonometry, Pascal tonometry, assessment of retinal blood flow velocity using the retinal function imager, as well as blood pressure and pulse measurements. RESULTS: Intraocular pressure decreased significantly in treated eyes while remaining stable in control eyes, indicating reliable application of brimonidine and brinzolamide drops. In contrast, retinal blood flow velocities did not demonstrate any significant differences between groups after both treatment rounds. CONCLUSIONS: Neither brimonidine nor brinzolamide appear to alter retinal blood flow velocity in a clinically relevant manner. The slight velocity changes detected in our study are likely physiologic fluctuations. Our findings do not support the rationale of a detrimental effect of topical brimonidine on ocular blood flow and hence brimonidine may be further administered for lowering intraocular pressure with the appropriate caution. However, our study is strongly limited by the small sample size and, thus, further research with larger cohorts of healthy volunteers and patients with glaucoma is needed to confirm the results. TRANSLATIONAL RELEVANCE: The study provides information about the effect of the topically administered antiglaucoma medications brimonidine and brinzolamide on the ocular blood flow and its regulation. The findings indicate that beside the lowering of IOP there is no evidence for an additional effect on the development of glaucoma.
format Online
Article
Text
id pubmed-8819484
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Association for Research in Vision and Ophthalmology
record_format MEDLINE/PubMed
spelling pubmed-88194842022-02-18 Comparative Assessment of Retinal Blood Flow Velocity Changes Following Brimonidine and Brinzolamide Administration Using Retinal Function Imaging Enz, Tim J. Bittner, Mario Tribble, James R. Williams, Pete A. Thiel, Michael A. Schmid, Martin K. Bachmann, Lucas M. Bochmann, Frank Transl Vis Sci Technol Article PURPOSE: Impaired ocular blood flow has been associated with the etiopathogenesis of glaucoma. Topical brimonidine lowers intraocular pressure, a major glaucoma risk factor. However, brimonidine's influence on retinal blood flow remains to be fully elucidated. Our aim was to compare the effect of topical brimonidine and brinzolamide administration on retinal blood flow velocity in second and third order vessels in healthy adults using the retinal function imager. METHODS: In 10 healthy probands between 23 and 32 years of age, one eye was randomly selected to receive 2 treatment rounds with 3 single doses of brimonidine 2 mg/mL and brinzolamide 10 mg/mL at 12-hour intervals each. The fellow eyes served as intra-individual controls. Immediately before the first drop and 2 hours after the last drop of each treatment round, all subjects were examined, including Goldmann tonometry, Pascal tonometry, assessment of retinal blood flow velocity using the retinal function imager, as well as blood pressure and pulse measurements. RESULTS: Intraocular pressure decreased significantly in treated eyes while remaining stable in control eyes, indicating reliable application of brimonidine and brinzolamide drops. In contrast, retinal blood flow velocities did not demonstrate any significant differences between groups after both treatment rounds. CONCLUSIONS: Neither brimonidine nor brinzolamide appear to alter retinal blood flow velocity in a clinically relevant manner. The slight velocity changes detected in our study are likely physiologic fluctuations. Our findings do not support the rationale of a detrimental effect of topical brimonidine on ocular blood flow and hence brimonidine may be further administered for lowering intraocular pressure with the appropriate caution. However, our study is strongly limited by the small sample size and, thus, further research with larger cohorts of healthy volunteers and patients with glaucoma is needed to confirm the results. TRANSLATIONAL RELEVANCE: The study provides information about the effect of the topically administered antiglaucoma medications brimonidine and brinzolamide on the ocular blood flow and its regulation. The findings indicate that beside the lowering of IOP there is no evidence for an additional effect on the development of glaucoma. The Association for Research in Vision and Ophthalmology 2022-02-01 /pmc/articles/PMC8819484/ /pubmed/35103799 http://dx.doi.org/10.1167/tvst.11.2.1 Text en Copyright 2022 The Authors https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License.
spellingShingle Article
Enz, Tim J.
Bittner, Mario
Tribble, James R.
Williams, Pete A.
Thiel, Michael A.
Schmid, Martin K.
Bachmann, Lucas M.
Bochmann, Frank
Comparative Assessment of Retinal Blood Flow Velocity Changes Following Brimonidine and Brinzolamide Administration Using Retinal Function Imaging
title Comparative Assessment of Retinal Blood Flow Velocity Changes Following Brimonidine and Brinzolamide Administration Using Retinal Function Imaging
title_full Comparative Assessment of Retinal Blood Flow Velocity Changes Following Brimonidine and Brinzolamide Administration Using Retinal Function Imaging
title_fullStr Comparative Assessment of Retinal Blood Flow Velocity Changes Following Brimonidine and Brinzolamide Administration Using Retinal Function Imaging
title_full_unstemmed Comparative Assessment of Retinal Blood Flow Velocity Changes Following Brimonidine and Brinzolamide Administration Using Retinal Function Imaging
title_short Comparative Assessment of Retinal Blood Flow Velocity Changes Following Brimonidine and Brinzolamide Administration Using Retinal Function Imaging
title_sort comparative assessment of retinal blood flow velocity changes following brimonidine and brinzolamide administration using retinal function imaging
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819484/
https://www.ncbi.nlm.nih.gov/pubmed/35103799
http://dx.doi.org/10.1167/tvst.11.2.1
work_keys_str_mv AT enztimj comparativeassessmentofretinalbloodflowvelocitychangesfollowingbrimonidineandbrinzolamideadministrationusingretinalfunctionimaging
AT bittnermario comparativeassessmentofretinalbloodflowvelocitychangesfollowingbrimonidineandbrinzolamideadministrationusingretinalfunctionimaging
AT tribblejamesr comparativeassessmentofretinalbloodflowvelocitychangesfollowingbrimonidineandbrinzolamideadministrationusingretinalfunctionimaging
AT williamspetea comparativeassessmentofretinalbloodflowvelocitychangesfollowingbrimonidineandbrinzolamideadministrationusingretinalfunctionimaging
AT thielmichaela comparativeassessmentofretinalbloodflowvelocitychangesfollowingbrimonidineandbrinzolamideadministrationusingretinalfunctionimaging
AT schmidmartink comparativeassessmentofretinalbloodflowvelocitychangesfollowingbrimonidineandbrinzolamideadministrationusingretinalfunctionimaging
AT bachmannlucasm comparativeassessmentofretinalbloodflowvelocitychangesfollowingbrimonidineandbrinzolamideadministrationusingretinalfunctionimaging
AT bochmannfrank comparativeassessmentofretinalbloodflowvelocitychangesfollowingbrimonidineandbrinzolamideadministrationusingretinalfunctionimaging